Download
Download by
Scanning QR Code
  • Download app

    Download app

  • Online Inquiry

    Log in to access Online Inquiry
+
Congratulations
You've successfully got advanced quotes worth 5000 HKD
Download APP >>
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
Futubull > Quotes > WVE Wave Life Sciences > Detailed Quotes

WVE Wave Life Sciences

Watchlist
3.750
+0.210+5.93%
Close 10/04 16:00 ET
3.75000.00%
Post Mkt Price 10/04 16:01 ET
Giving away premium quotes worth 5000 HKD/year to unlock more data
Get NOW
High
3.770
Open
3.640
Turnover
746.26K
Low
3.352
Pre Close
3.540
Volume
207.66K
Market Cap
325.58M
P/E(TTM)
Loss
52wk High
5.220
Shares
86.82M
P/E(Static)
Loss
52wk Low
1.160
Float Cap
55.81M
Bid/Ask %
85.71%
Historical High
56.000
Shs Float
14.88M
Volume Ratio
0.94
Historical Low
1.160
Dividend TTM
--
Div Yield TTM
--
P/B
10.53
Dividend LFY
--
Div Yield LFY
--
Turnover Ratio
1.40%
Amplitude
11.82%
Avg Price
3.593
Lot Size
1
Float Cap
55.81M
Bid/Ask %
85.71%
Historical High
56.000
Shs Float
14.88M
Volume Ratio
0.94
Historical Low
1.160
Dividend TTM
--
P/B
10.53
Dividend LFY
--
Turnover Ratio
1.40%
Amplitude
11.82%
Avg Price
3.593
Lot Size
1
Price Forecast

No Data

News

Comment

Company Overview More
Wave Life Sciences Ltd., a clinical stage genetic medicine company, designs, optimizes, and produces novel stereopure oligonucleotides through PRISM, a discovery and drug developing platform. It is developing oligonucleotides target ribonucleic acid to reduce the expression of disease-promoting proteins or restore the production of functional proteins, or modulate protein expression. The company also develops WVE-004, a C9orf72 molecule for the treatment of amyotrophic lateral sclerosis and frontotemporal dementia; WVE-003, a mutant huntingtin SNP3 molecule for the treatment of Huntington’s disease; WVE-N531, an Exon 53 molecule for the treatment of Duchenne muscular dystrophy; and ATXN3, a discovery stage program for the treatment of spinocerebellar ataxia 3, as well as multiple preclinical programs for CNS disorders. In addition, it focuses on developing GalNAc-conjugated AIMers to treat hepatic indications comprising Alpha-1 antitrypsin deficiency (AATD); and two preclinical programs, such as Usher syndrome type 2A (USH2A) and retinitis pigmentosa due to a P23H mutation in the RHO gene (RhoP23H) for the treatment of retinal diseases. It has collaboration agreements with Pfizer Inc., Takeda Pharmaceutical Company Limited, University of Oxford, University of Massachusetts, Western Washington University, Grenoble Institute of Neurosciences, IRBM S.p.A, University of Louisville, and University College London. The company was incorporated in 2012 and is based in Singapore.
CEO: Bolno M.B.A., M.D., MBA, Paul B.
Market: NASDAQ
Futu Hot List
USHKCN
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist
Back to the Top